Membrane-Disrupting Molecules as Therapeutic Agents: A Cautionary Note

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Membrane-disrupting molecules can interact with lipid bilayers through different mechanisms.
• Aggregates of Triton X-100 cause catastrophic membrane rupture, whereas monomers induce mild leakage.
• This aggregation-dependent duplicity influences therapeutic potential.

Purpose of the Study:

• To investigate the differential effects of monomeric and aggregated membrane-disrupting molecules on membrane integrity.
• To design and evaluate novel therapeutic agents with improved selectivity by controlling molecular aggregation.
• To explore the potential of exploiting membrane lipid composition differences for targeted drug delivery.

Main Methods:

• Mechanistic studies using Triton X-100 to elucidate aggregation-dependent membrane disruption.
• Design and synthesis of Amphotericin B and l-phenylalanine derivatives with modified aggregation properties.
• In vitro and animal studies to assess antifungal, antibacterial, and hemolytic activities and toxicity.

Main Results:

• Triton X-100 aggregates induce catastrophic membrane rupture, while monomers cause mild leakage.
• Amphotericin B derivatives with reduced aggregation showed similar efficacy but lower toxicity in animal models.
• l-phenylalanine derivatives demonstrated that monomers possess antibacterial activity, while aggregates exhibit both antibacterial and hemolytic activity.

Conclusions:

• Controlling the aggregation state of membrane-disrupting molecules is crucial for therapeutic applications, with monomers offering greater selectivity.
• Developing agents that minimize aggregation can lead to reduced toxicity and improved therapeutic profiles.
• Future research should explore targeted drug design for specific membrane compositions, such as those in coronaviruses.